These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35940451)

  • 1. Elevated salivary kynurenic acid levels related to enlarged choroid plexus and severity of clinical phenotypes in treatment-resistant schizophrenia.
    Huang J; Tong J; Zhang P; Zhou Y; Li Y; Tan S; Wang Z; Yang F; Kochunov P; Chiappelli J; Tian B; Tian L; Hong LE; Tan Y
    Brain Behav Immun; 2022 Nov; 106():32-39. PubMed ID: 35940451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the immune-kynurenine pathway in treatment-resistant schizophrenia.
    Chen W; Tian Y; Gou M; Wang L; Tong J; Zhou Y; Feng W; Li Y; Chen S; Liu Y; Wang Z; Pan S; Zhang P; Huang J; Yang X; Li CR; Tian L; Hong LE; Tan Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Mar; 130():110926. PubMed ID: 38147973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum kynurenine metabolites might not be associated with risk factors of treatment-resistant schizophrenia.
    Huang J; Zhang P; Zhou Y; Tong J; Cui Y; Tan S; Wang Z; Yang F; Kochunov P; Tian B; Tian L; Hong LE; Tan Y
    J Psychiatr Res; 2022 Jan; 145():339-346. PubMed ID: 34776248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Plasma Kynurenic Acid Levels are Associated with Impaired Attention/Vigilance and Social Cognition in Patients with Schizophrenia.
    Huang X; Ding W; Wu F; Zhou S; Deng S; Ning Y
    Neuropsychiatr Dis Treat; 2020; 16():263-271. PubMed ID: 32158211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia.
    Szymona K; Zdzisińska B; Karakuła-Juchnowicz H; Kocki T; Kandefer-Szerszeń M; Flis M; Rosa W; Urbańska EM
    Neurotox Res; 2017 Jul; 32(1):17-26. PubMed ID: 28275903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tryptophan challenge in individuals with schizophrenia and healthy controls: acute effects on circulating kynurenine and kynurenic acid, cognition and cerebral blood flow.
    Hare SM; Adhikari BM; Mo C; Chen S; Wijtenburg SA; Seneviratne C; Kane-Gerard S; Sathyasaikumar KV; Notarangelo FM; Schwarcz R; Kelly DL; Rowland LM; Buchanan RW
    Neuropsychopharmacology; 2023 Oct; 48(11):1594-1601. PubMed ID: 37118058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance.
    Chiappelli J; Pocivavsek A; Nugent KL; Notarangelo FM; Kochunov P; Rowland LM; Schwarcz R; Hong LE
    JAMA Psychiatry; 2014 Jul; 71(7):761-8. PubMed ID: 24806441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of neuroactive metabolites of the tryptophan pathway on working memory and cortical thickness in schizophrenia.
    Huang J; Tong J; Zhang P; Zhou Y; Cui Y; Tan S; Wang Z; Yang F; Kochunov P; Chiappelli J; Tian B; Tian L; Tan Y; Hong LE
    Transl Psychiatry; 2021 Apr; 11(1):198. PubMed ID: 33795641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple serum anti-glutamate receptor antibody levels in clozapine-treated/naïve patients with treatment-resistant schizophrenia.
    He J; Li J; Wei Y; He Z; Liu J; Yuan N; Zhou R; He X; Ren H; Gu L; Liao Y; Chen X; Tang J
    BMC Psychiatry; 2024 Apr; 24(1):248. PubMed ID: 38566016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased plasma level of kynurenic acid in drug-free patients with first-episode schizophrenia compared to patients with chronic schizophrenia and healthy controls: preliminary data.
    Ding W; Wu F; Zhou S; Li H; Wang R; Ning Y
    Nord J Psychiatry; 2022 Aug; 76(6):451-456. PubMed ID: 34928781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary comparative analysis of kynurenine pathway metabolites in chronic ketamine users, schizophrenic patients, and healthy controls.
    Zhang Z; Zhang M; Luo Y; Ni X; Lu H; Wen Y; Fan N
    Hum Psychopharmacol; 2020 Jul; 35(4):e2738. PubMed ID: 32352599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.
    de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F
    Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats.
    Baratta AM; Viechweg SS; Mong JA; Pocivavsek A
    J Vis Exp; 2018 Aug; (138):. PubMed ID: 30176006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia.
    Itahashi T; Noda Y; Iwata Y; Tarumi R; Tsugawa S; Plitman E; Honda S; Caravaggio F; Kim J; Matsushita K; Gerretsen P; Uchida H; Remington G; Mimura M; Aoki YY; Graff-Guerrero A; Nakajima S
    Neuroimage Clin; 2021; 32():102852. PubMed ID: 34638035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choroid Plexus Enlargement and Allostatic Load in Schizophrenia.
    Zhou YF; Huang JC; Zhang P; Fan FM; Chen S; Fan HZ; Cui YM; Luo XG; Tan SP; Wang ZR; Feng W; Yuan Y; Yang FD; Savransky A; Ryan M; Goldwaser E; Chiappelli J; Rowland LM; Kochunov P; Tan YL; Hong LE
    Schizophr Bull; 2020 Apr; 46(3):722-731. PubMed ID: 31603232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients.
    Iasevoli F; D'Ambrosio L; Notar Francesco D; Razzino E; Buonaguro EF; Giordano S; Patterson TL; de Bartolomeis A
    Schizophr Res; 2018 Dec; 202():217-225. PubMed ID: 29934250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New prospects for antipsychotic treatment - the role of the kynurenine pathway].
    Karakuła-Juchnowicz H; Flis M; Szymona K; Kuczyńska M; Stelmach E; Kowal-Popczak A
    Psychiatr Pol; 2014; 48(6):1167-77. PubMed ID: 25717486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
    Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
    Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid kynurenine and kynurenic acid concentrations are associated with coma duration and long-term neurocognitive impairment in Ugandan children with cerebral malaria.
    Holmberg D; Franzén-Röhl E; Idro R; Opoka RO; Bangirana P; Sellgren CM; Wickström R; Färnert A; Schwieler L; Engberg G; John CC
    Malar J; 2017 Jul; 16(1):303. PubMed ID: 28754152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia.
    Chiappelli J; Rowland LM; Notarangelo FM; Wijtenburg SA; Thomas MAR; Pocivavsek A; Jones A; Wisner K; Kochunov P; Schwarcz R; Hong LE
    Neuropsychopharmacology; 2018 Jul; 43(8):1706-1711. PubMed ID: 29728648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.